ICARIA-MM: Haematological laboratory abnormalities in patients receiving SARCLISA + Pd vs. Pd alone1

The denominator used for the percentage calculation is the number of patients with at least 1 evaluation of the laboratory test during the considered observation period.1
Adapted from SARCLISA Summary of Product Characteristics.1

30.3% patients treated with SARCLISA had neutropenic complications.1

Full blood cell counts should be monitored periodically during treatment.1

Overall discontinuation rate did not increase with addition of SARCLISA to Pd2

You are now leaving the website.

By clicking on this link, you will be leaving this Sanofi hosted website, and, depending on the link, will be redirected to either another Sanofi website (for example, to view the Sanofi Privacy Policy) or an independent third-party website.
Sanofi has no control over the content or availability of third-party sites or resources that are linked to, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. The existence of a link between this website and any third party site or resource in no way implies that Sanofi in any way approves of the content of these sites or resources, or any use to which such content maybe put.

Please ensure that you read the legal and privacy policy sections of any website to which you link.